Ascendis Pharma A/S
ASNDNASDAQHealthcare● Active
$205.32
$-5.13(-2.44%)
Market Cap$12.7B
P/E Ratio—
52W High$250.74
52W Low$160.86
Ascendis Pharma A/S (ASND) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ASND · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.69B | $0.36B | $0.27B | $0.05B | $0.01B |
| Cost of Revenue | $0.10B | $0.04B | $0.04B | $0.01B | $0.00B |
| Gross Profit | $0.59B | $0.32B | $0.22B | $0.04B | $0.00B |
| Gross Margin %(computed) | 85.08% | 87.83% | 83.36% | 76.28% | 54.71% |
| Operating Expenses | |||||
| R&D Expenses | $0.28B | $0.31B | $0.41B | $0.38B | $0.30B |
| G&A Expenses | $0.00B | $0.28B | $0.26B | $0.22B | $0.00B |
| Total Operating Expenses | $0.72B | $0.60B | $0.68B | $0.60B | $0.46B |
| Operating Income | ($0.13B) | ($0.28B) | ($0.46B) | ($0.56B) | ($0.45B) |
| Operating Margin %(computed) | -18.92% | -76.66% | -170.79% | — | — |
| Interest Income | $0.01B | $0.01B | $0.02B | $0.01B | $0.00B |
| Interest Expense | $0.08B | $0.07B | $0.04B | $0.03B | $0.00B |
| Income Before Tax | ($0.20B) | ($0.37B) | ($0.47B) | ($0.58B) | ($0.38B) |
| Income Tax Expense | $0.01B | $0.00B | $0.01B | $0.01B | ($0.00B) |
| Net Income | ($0.22B) | ($0.38B) | ($0.48B) | ($0.58B) | ($0.38B) |
| Net Margin %(computed) | -31.67% | -103.97% | -180.51% | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-3.62 | $-6.53 | $-8.55 | $-10.40 | $-7.00 |
| Wtd Avg Shares | 0.06B | 0.06B | 0.06B | 0.06B | 0.05B |
| EBITDA | ($0.11B) | ($0.29B) | ($0.41B) | ($0.53B) | ($0.36B) |
| EBITDA Margin %(computed) | -16.47% | -79.76% | -154.16% | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · EUR · B
Explore more Ascendis Pharma A/S data
About Ascendis Pharma A/S (ASND) Income Statement
Ascendis Pharma A/S (ASND) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, ASND reported revenue of $0.69B, gross profit of $0.59B (gross margin 85.08%), and net income of ($0.22B) — a net profit margin of -31.67%.
Frequently asked questions
ASND · 4 questionsAscendis Pharma A/S (ASND) reported revenue of $0.69B for 2025, up 90.2% year-over-year.
ASND revenueASND salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08